Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)
ID: 353243Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $4M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353243

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-010.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Mar 27, 2024, 12:00 AM UTC
  4. 4
    Due Jun 28, 2024, 12:00 AM UTC
Description

The National Institutes of Health (NIH) has announced a funding opportunity titled "Feasibility of Novel Diagnostics for TB in Endemic Countries" (FEND for TB), aimed at enhancing tuberculosis (TB) diagnostics in regions where the disease is prevalent. This initiative seeks to evaluate early-stage diagnostic tests and strategies, particularly those targeting vulnerable populations such as people living with HIV, while adhering to existing clinical algorithms. The total funding available for this opportunity is approximately $5.5 million, anticipated to support 1-2 awards over a five-year period, with applications due by June 29, 2024. Interested applicants can find more information and submit their proposals electronically through Grants.gov, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-AI-24-010-Full-Announcement.html
Aug 24, 2024, 2:22 AM UTC
RFA-AI-24-010.html
Aug 24, 2024, 2:22 AM UTC
The National Institutes of Health (NIH) has announced a funding opportunity titled "Feasibility of Novel Diagnostics for TB in Endemic Countries" (FEND for TB) to enhance tuberculosis (TB) diagnostics in countries where TB is prevalent. The aim is to evaluate early-stage diagnostic tests and strategies, including those targeting specific populations like people living with HIV. This funding opportunity (RFA-AI-24-010) is open for applications from eligible organizations, with a total of $5.5 million anticipated for 1-2 awards over five years. The applications must propose innovative early-stage technologies and include detailed evaluation plans, along with demonstrating collaboration with clinical sites in endemic areas. Critical topics of interest include point-of-care diagnostics, non-sputum specimen analysis, and rapid drug susceptibility testing. Applications will not be considered if they involve clinical trials or the establishment of new clinical infrastructure. The review process will evaluate the significance, innovation, and approach of the proposed projects. Eligible applicants include a broad range of institutions and organizations, including higher education institutions, non-profits, and foreign organizations. All applications must comply with NIH guidelines and be submitted electronically through Grants.gov, with a due date of June 29, 2024.
Similar Opportunities
International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.
Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk," aimed at supporting research into the immunometabolic changes induced by HIV in individuals undergoing combination antiretroviral therapy. This initiative seeks to investigate how these alterations affect immune responses and increase the risk of subsequent infections, specifically tuberculosis (TB) and hepatitis B virus (HBV). The funding opportunity is particularly significant for advancing understanding in the field of HIV-related health risks and aims to foster innovative research approaches, including the use of machine learning and AI to identify biomarkers and therapeutic targets. Eligible applicants can receive up to $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html.
Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
Advancing TB Prevention, Detection and Treatment in the Philippines
Philippines USAID-Manila
USAID/Philippines is forecasting a cooperative agreement opportunity titled "Advancing TB Prevention, Detection and Treatment in the Philippines," aimed at eliminating tuberculosis (TB) in the country. The initiative seeks to partner with capable local organizations, including NGOs, universities, and consortiums, that have experience in infectious disease projects, particularly TB, to contribute to a future five-year project with an estimated funding of $25 million. This project is critical for enhancing health outcomes in the Philippines, addressing a significant public health challenge. Interested organizations can find more information and submission requirements on the USAID/Philippines website or contact Ma. Belinda De La Torre at +63-2-301-4927 or via email at ROAA-Admin-Manila@usaid.gov for further inquiries.
Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
Tuberculosis Innovations and Health Systems Strengthening in the Philippines
Philippines USAID-Manila
The Philippines USAID-Manila is forecasting a cooperative agreement opportunity titled "Tuberculosis Innovations and Health Systems Strengthening in the Philippines." This initiative aims to engage capable organizations, including NGOs, universities, and for-profit entities, to collaborate with USAID in reducing and eliminating tuberculosis (TB) in the Philippines. The program is critical for enhancing health systems and addressing TB challenges in the region. Interested parties can access the complete Request for Information (RFI) package through the USAID/Philippines website or request a copy via email at manila-roaa-rfp@usaid.gov, with the subject line "RFI-492-17-OH-002." The opportunity is categorized as discretionary funding, with a cost-sharing requirement, and is expected to result in one award. For further inquiries, contact Gracelda M. Laspinas at (632) 3014929.
Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive measures for HIV and its associated complications. This grant opportunity encourages eligible applicants, including various educational institutions and community organizations, to create innovative product development plans that align with FDA guidelines, facilitating the submission of Investigational New Drug (IND) applications. With a total estimated funding of $225,000 available for individual projects, applications are due by December 5, 2026, and must adhere to specific guidelines emphasizing scientific merit and compliance. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link provided in the announcement.
Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is inviting applications for the Global Infectious Disease Research Training Program (D43 Clinical Trial Optional), aimed at enhancing research capacity in low- and middle-income countries (LMICs) regarding infectious diseases. This program encourages collaborative applications from U.S. and LMIC institutions, focusing on critical areas such as neglected tropical diseases and co-infections in HIV patients, while excluding HIV/AIDS as a primary focus. Successful applicants will develop structured training curricula, mentorship pairings, and research skills relevant to local health priorities, with annual budgets capped at $230,000 for a maximum project period of five years. Interested parties should note that the application deadline is August 6, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.